Amplified Benefit of Clopidogrel Versus Aspirin in Patients With Diabetes Mellitus


Phase N/A Results


The event rate per year was 12.7% in the 7,594 nondiabetic patients randomized to aspirin and 11.8% in the 7,639 nondiabetic patients randomized to clopidogrel (p = 0.096). For diabetic patients who received insulin at baseline, the annual event rates for the primary composite end point were higher: 17.7% in the clopidogrel group and 21.5% in the aspirin group, with an absolute risk reduction of 3.8% (p = 0.106). The incidence of rehospitalization for bleeding events and for either ischemic or bleeding events was significantly lower with clopidogrel therapy than with aspirin therapy (p = 0.031 and p = 0.047, respectively) with 13.3% in the clopidogrel group compared to 15.6% in the aspirin group experiencing bleeding or ischemic events.